Nasdaq ikna.

Follow. BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...May 18, 2023 · IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ... Nasdaq | IKNA U.S.: Nasdaq Ikena Oncology Inc. Watch list Set a price target alert After Hours Last Updated: Nov 9, 2023 6:00 p.m. EST Delayed quote $ 1.2500 -0.08 -6.02% …Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies Stocks

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today ...Jun 28, 2021 · Every investor in Ikena Oncology, Inc. (NASDAQ:IKNA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies ...

The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on Thursday, November 9, 2023.The analyst firm set a price target for 11.00 expecting IKNA to rise ...

Near Intelligence's stock rallies 43% after Benchmark starts coverage with speculative buy rating. Near Intelligence Inc.'s stock NIR, +51.45% rallied 43% Friday, after Benchmark initiated coverage of the stock with a speculative buy rating with analyst Mark Zgutowicz arguing it's undervalued.Nov 9, 2023 · Selected Balance Sheet Items: September 30, 2023 December 31, 2022: Cash and cash equivalents $ 121,277 $ 59,919 Marketable securities $ 75,656 Mar 14, 2023 · Financial Results for the Year Ended December 31, 2022. As of December 31, 2022, Ikena had $156.9 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient ... BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today ...

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

Nov 9, 2023 · Selected Balance Sheet Items: September 30, 2023 December 31, 2022: Cash and cash equivalents $ 121,277 $ 59,919 Marketable securities $ 75,656

Ikena Oncology, Inc. is traded on the NASDAQ under the ticker symbol "IKNA". What is Ikena Oncology's primary industry? Company operates in the Healthcare ...Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...ABOUT THIS EVENT Ikena Oncology, Inc (Nasdaq: IKNA) rings the Nasdaq Closing Bell remotely from across the country. Mark Manfredi, Ph.D., President & CEO, rings the Closing Bell alongside the ...BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON--(BUSINESS WIRE)--May 13, 2021-- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced financial results for the quarter ended March 31, 2021.

When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...Mar 7, 2023 · Follow. BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ... Biogen Inc. (NASDAQ:BIIB) announced negative topline results from the Phase 3 STAR study of timrepigene emparvovec, an investigational gene therapy for the potential treatment of choroideremia.Dec 1, 2023 · In the previous quarter, Ikena Oncology (NASDAQ:IKNA) reported ($0.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.04. Learn more on analysts' earnings estimate vs. IKNA's actual earnings. Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology ...Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has gone decline by -62.23 in comparison to its previous close of 4.13, however, the company has experienced a -61.58% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology,Ikena Oncology Inc (NASDAQ: IKNA) is garnering attention with its oncology-focused pipeline, and the company's recent developments have raised optimism in the medical community.

Shares of Chembio Diagnostics, Inc. (NASDAQ:CEMI) got a boost, shooting 57% to $5.53 after the company announced the commercial launch of a test to differentiate between COVID-19 and the Flu.NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become ...

3 mai 2022 ... Maude Tessier joins Seismic after serving as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where ...Take Ikena Oncology (NASDAQ: IKNA) for instance. All in all, the company just announced today that the Food and Drug Administration (FDA) has granted a Fast Track designation for IK-930.According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...According to the issued ratings of 4 analysts in the last year, the consensus rating for Ikena Oncology stock is Buy based on the current 4 buy ratings for IKNA. The average twelve-month price prediction for Ikena Oncology is $11.67 with a high price target of $13.00 and a low price target of $11.00. Learn more on IKNA's analyst rating history.When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...Near Intelligence's stock rallies 43% after Benchmark starts coverage with speculative buy rating. Near Intelligence Inc.'s stock NIR, +51.45% rallied 43% Friday, after Benchmark initiated coverage of the stock with a speculative buy rating with analyst Mark Zgutowicz arguing it's undervalued.IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ...

Ikena Oncology, Inc. (NASDAQ:IKNA) Achilles Therapeutics plc (NASDAQ:ACHL) Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates . Photo by Thought Catalog on Unsplash.

19 oct. 2022 ... (Nasdaq: IKNA, “Ikena”), una compañía de oncología específica que forja un nuevo territorio en el tratamiento del cáncer dirigido por el ...

Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...17 avr. 2023 ... BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA ... NASDAQ:IKNA. IKNA Rankings. #5626 Ranked by Market Cap. #614 ...Investing.com - Ikena Oncology (NASDAQ: IKNA) divulgou lucro por ação (LPA) de $-0,40 no terceiro trimestre, $0,03 acima da estimativa dos analistas de $-0,43.A receita trimestral foi de $1,19M, contra o consenso de mercado de $2,84M. As ações da Ikena Oncology fecharam em $1,33. Elas caíram -69,07% nos últimos 3 meses e caíram …The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market ® that are classified as either biotechnology or pharmaceutical according to the Industry ...Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in...17 déc. 2021 ... ... (NASDAQ: ADGI), Icosavax (NASDAQ: ICVX), Imago BioSciences (NASDAQ: IMGO), Ikena Oncology (NASDAQ: IKNA), Nuvation Bio (NYSE: NUVB), Sana ...Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology ...Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com. Overview News Ikena Oncology Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.62 Market Cap 72.39 M Public Float N/A N/A …BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

Nov 24, 2023 · According to the issued ratings of 4 analysts in the last year, the consensus rating for Ikena Oncology stock is Buy based on the current 4 buy ratings for IKNA. The average twelve-month price prediction for Ikena Oncology is $11.67 with a high price target of $13.00 and a low price target of $11.00. Learn more on IKNA's analyst rating history. BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...8 août 2023 ... Hims & Hers Health (NYSE:HIMS) stock is climbing more than 16% alongside increasing revenue in Q2. Ikena Oncology (NASDAQ:IKNA) shares are ...Instagram:https://instagram. the rock snickersaivsx mutual fundnobl dividendwhen is a good time to buy bonds BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented ...Mar 17, 2022 · BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ... where can i sell an xbox 360day trader taxes Aug 10, 2023 · Financial Results for the Quarter Ended June 30, 2023. As of June 30, 2023, Ikena had $157.3 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ... biggest losers in stock market today Dow jones falls over 200 points on thursday; the nasdaq and s&p 500 also trade lower. Krispy kreme reports downbeat results for third quarter; energy shares rise by 0.3%. …Find the latest Financials data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com. Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.